We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Photonic Crystal Biosensors Detect Protein-DNA Interactions

By LabMedica International staff writers
Posted on 15 Oct 2008
Scientists have developed a new class of disposable, microplate-based optical biosensors capable of detecting protein-DNA interactions. More...
Based on the characteristics of photonic crystals, the biosensors are suitable for the rapid identification of inhibitors of protein-nucleic acid and protein-protein interactions.

"Protein-DNA interactions are essential for fundamental cellular processes such as transcription, DNA damage repair, and apoptosis,” said Dr. Paul Hergenrother, a professor of chemistry and an affiliate of the University of Illinois Institute for Genomic Biology (U of I; Urbana-Champaign; IL, USA). "Screening for compounds that inhibit particular kinds of protein-DNA binding is a very important step in drug development.”

Developed by Dr. Brian Cunningham, a U of I professor of electrical and computer engineering, the photonic crystal biosensors consist of a low-refractive-index polymer grating coated with a film of high-refractive-index titanium oxide, attached to the bottom of a standard 384-well microplate. Each well functions as a tiny test tube with a biosensor in the bottom.

"First, we selectively attach a biomolecule, such as DNA, to the bottom of each well. Then we see how that biomolecule interacts with other molecules, including drugs,” said Dr. Cunningham. By examining the light reflected from the photonic crystal, the researchers can determine when molecules are added to, or removed from, the crystal surface. The measurement technique can be used, for example, in a high-throughput screening mode to rapidly identify molecules and compounds that prevent DNA-protein binding.

The researchers demonstrated the new technology by examining two very different protein-DNA interactions. The first was the bacterial toxin-antitoxin system MazEF, which binds to DNA in a sequence-specific manner and is believed to be responsible for the maintenance of resistance-encoding plasmids in certain infectious bacteria. The second was the human apoptosis-inducing factor (AIF), a protein that binds to chromosomal DNA in a DNA-sequence-independent manner.

The photonic crystal biosensor technology was additionally utilized in a screen for inhibitors of the AIF-DNA interaction, and through this screen, aurin tricarboxylic acid was identified as the first in vitro inhibitor of AIF. "Aurin tricarboxylic acid displayed about 80% inhibition of AIF-DNA binding,” Dr. Hergenrother said. "Aurin tricarboxylic acid was the only compound to exhibit significant inhibition out of approximately 1,000 compounds screened.”

While the photonic crystal biosensor was demonstrated only for protein-DNA interactions, equivalent studies with protein-RNA interactions and protein-protein interactions are also possible, according to Dr. Cunningham. "We also could grow cancer cells on the photonic crystal surface, and see how different drugs affect cell growth.”

The researchers described their research in the July 18, 2008, issue of the journal ACS Chemical Biology.

Related Links:
University of Illinois Institute for Genomic Biology



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
TRAb Immunoassay
Chorus TRAb
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.